Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Pluvicto improves survival in metastatic hormone-sensitive prostate cancer across patient subgroups.

NVS

$150.17

-$1.23 -0.81%

Pluvicto improves survival in metastatic hormone-sensitive prostate cancer across patient subgroups.

Name: Pluang-Trading US Stock Crypto
Availability: InStock
Rating: 4.75 (118772 reviews)
Author: pluang

Company Fundamentals

31 May 2026

Novartis

View Source

Bullish

Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients, regardless of disease volume or presentation. The PSMAddition trial showed a 28% reduction in risk of progression or death, supporting early treatment use. Safety profiles were consistent, with manageable side effects. Novartis is also advancing actinium-based radioligand therapy with promising Phase 1 data and ongoing Phase 3 trials, aiming to expand treatment options for prostate cancer patients globally.

More News (NVS)